Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma

View through CrossRef
<p>Proximity labeling identifies histone acetylase SIRT1 as a direct KDM4C nuclear interactor and a novel KDM4C–SIRT1–DUSP2 axis regulating ERK activity in PDAC. <b>A,</b> Validating biotinylation activity by KDM4C-miniTurboID. AsPC1 cells were transfected with KDM4C-miniTurboID and then treated with 50 μmol/L biotin 24 hours after transfection for 30 minutes. Cells were then lysed and the whole lysates probed for biotin by streptavidin–HRP along with “untransfected” and “KDM4C-miniTurboID without biotin” as controls. <b>B,</b> Cytoscape analysis of the biotinylated nuclear proteins by KDM4C-miniTurboID, with annotated biological processes. <b>C,</b> List of high-confidence nuclear KDM4C interactors based on proximity labeling experiment. The values shown are the abundance ratio between “KDM4C-miniTurboID + biotin” over “KDM4C-miniTurboID without biotin”. <b>D,</b> KDM4C co-immunoprecipitation confirms binding to SIRT1 in PDAC cells but not to PARP1 or ZNF148. IgG isotype antibody was used as a control for nonspecific binding. <b>E,</b> Graphical illustration of KDM4C domain-specific deletion constructs: FL = full-length KDM4C construct, ΔTudor = Tudor domain–deleted KDM4C, ΔPHD = PHD-deleted KDM4C, and ΔJMJ = JMJ domain–deleted KDM4C construct. All constructs are HA-tagged for immunoprecipitation. <b>F,</b> The Tudor domain is responsible for KDM4C binding to SIRT1. HEK293 cells were cotransfected with Flag-tagged SIRT1 construct and either FL KDM4C or a KDM4C domain–deleted construct, and then the cells were lysed, and the HA-enriched eluates for respective samples were probed for SIRT1 using anti-Flag. All constructs could pull down SIRT1 except ΔTudor. <b>G,</b> Venn diagram illustrating high degree of correlation between the genes with increased H3K36me3 and H3K27Ac peaks at the promoter region in <i>KDM4C</i> KO cells. Integrating ChIP-seq with the RNA-seq data results in a list of 16 genes, including the protein phosphatase <i>DUSP2</i>, which targets ERK phosphorylation. <b>H,</b> RT-qPCR of <i>DUSP</i> 1, 2, 4, 5, and 6 in AsPC1 control cells and <i>KDM4C</i> KO shows <i>DUSP2</i> has the highest FC increase in mRNA expression, *, <i>P</i> ≤ 0.05; **, <i>P</i> ≤ 0.01, via unpaired <i>t</i> test. <b>I,</b> Western blot shows increased DUSP2 protein levels in <i>KDM4C</i>-null clones.</p>
Title: Figure 6 from The Lysine Demethylase KDM4C Is an Oncogenic Driver and Regulates ERK Activity in KRAS-Mutant Pancreatic Ductal Adenocarcinoma
Description:
<p>Proximity labeling identifies histone acetylase SIRT1 as a direct KDM4C nuclear interactor and a novel KDM4C–SIRT1–DUSP2 axis regulating ERK activity in PDAC.
<b>A,</b> Validating biotinylation activity by KDM4C-miniTurboID.
AsPC1 cells were transfected with KDM4C-miniTurboID and then treated with 50 μmol/L biotin 24 hours after transfection for 30 minutes.
Cells were then lysed and the whole lysates probed for biotin by streptavidin–HRP along with “untransfected” and “KDM4C-miniTurboID without biotin” as controls.
<b>B,</b> Cytoscape analysis of the biotinylated nuclear proteins by KDM4C-miniTurboID, with annotated biological processes.
<b>C,</b> List of high-confidence nuclear KDM4C interactors based on proximity labeling experiment.
The values shown are the abundance ratio between “KDM4C-miniTurboID + biotin” over “KDM4C-miniTurboID without biotin”.
<b>D,</b> KDM4C co-immunoprecipitation confirms binding to SIRT1 in PDAC cells but not to PARP1 or ZNF148.
IgG isotype antibody was used as a control for nonspecific binding.
<b>E,</b> Graphical illustration of KDM4C domain-specific deletion constructs: FL = full-length KDM4C construct, ΔTudor = Tudor domain–deleted KDM4C, ΔPHD = PHD-deleted KDM4C, and ΔJMJ = JMJ domain–deleted KDM4C construct.
All constructs are HA-tagged for immunoprecipitation.
<b>F,</b> The Tudor domain is responsible for KDM4C binding to SIRT1.
HEK293 cells were cotransfected with Flag-tagged SIRT1 construct and either FL KDM4C or a KDM4C domain–deleted construct, and then the cells were lysed, and the HA-enriched eluates for respective samples were probed for SIRT1 using anti-Flag.
All constructs could pull down SIRT1 except ΔTudor.
<b>G,</b> Venn diagram illustrating high degree of correlation between the genes with increased H3K36me3 and H3K27Ac peaks at the promoter region in <i>KDM4C</i> KO cells.
Integrating ChIP-seq with the RNA-seq data results in a list of 16 genes, including the protein phosphatase <i>DUSP2</i>, which targets ERK phosphorylation.
<b>H,</b> RT-qPCR of <i>DUSP</i> 1, 2, 4, 5, and 6 in AsPC1 control cells and <i>KDM4C</i> KO shows <i>DUSP2</i> has the highest FC increase in mRNA expression, *, <i>P</i> ≤ 0.
05; **, <i>P</i> ≤ 0.
01, via unpaired <i>t</i> test.
<b>I,</b> Western blot shows increased DUSP2 protein levels in <i>KDM4C</i>-null clones.
</p>.

Related Results

Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract C081: The lysine demethylase KDM4C is an oncogenic driver in pancreatic ductal adenocarcinoma
Abstract Deregulation of proteins involved in chromatin regulation is common in pancreatic ductal adenocarcinoma (PDAC), occurring via both genomic and non-genomic m...
Kras Plays An Important Role In Generating Differentiated Blood Cells
Kras Plays An Important Role In Generating Differentiated Blood Cells
Abstract Background Kras is a small GTPase essential for mouse embryonic development. Although Kras-/- fetal liver cells reconst...
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
The molecular mechanism underlying KRAS regulation on STK31 expression in Pancreatic ductal adenocarcinoma
Abstract KRAS mutations are common in pancreatic ductal adenocarcinoma (PDAC) but targeting mutant KRAS is still challenging. Kinase inhibitors are ideal targeted therapeut...

Back to Top